Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Edwards Lifesciences Corp EW

Healthcare Medical Devices
Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter... see more

Recent & Breaking News (NYSE:EW)

EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA

PR Newswire May 7, 2023

EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS

PR Newswire April 26, 2023

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2023

PR Newswire April 19, 2023

EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS

PR Newswire March 6, 2023

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS

PR Newswire January 31, 2023

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023

PR Newswire January 24, 2023

EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

PR Newswire January 5, 2023

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

PR Newswire December 8, 2022

EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

PR Newswire December 8, 2022

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

PR Newswire November 27, 2022

EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE

PR Newswire November 1, 2022

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS

PR Newswire October 27, 2022

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022

PR Newswire October 20, 2022

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

PR Newswire September 17, 2022

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

PR Newswire September 15, 2022

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

PR Newswire September 12, 2022

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

PR Newswire August 17, 2022

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS

PR Newswire July 28, 2022

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

PR Newswire July 21, 2022

EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE

PR Newswire May 23, 2022